Trials / Not Yet Recruiting
Not Yet RecruitingNCT02933229
The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study
- Status
- Not Yet Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 300 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies
Conditions
- Helicobacter Pylori
- the Operative Link on Gastric Intestinal Metaplasia
- Operative Link on Gastric Intestinal Assessment
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | biopsy | patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology. |
| DRUG | H. pylori eradication | H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin. If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication. |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2031-10-01
- Completion
- 2031-10-01
- First posted
- 2016-10-14
- Last updated
- 2016-10-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02933229. Inclusion in this directory is not an endorsement.